Why intermittent rapamycin dosing is the research focus
Rapamycin is an FDA-approved transplant drug. Researchers now study whether weekly, not daily, dosing changes what it does.
TL;DR
- Rapamycin is FDA-approved (Food and Drug Administration) only for transplant rejection, not longevity.
- Researchers study intermittent rapamycin dosing because it may spare mTORC2, the complex tied to side effects.
- Mouse studies show lifespan gains; human evidence stays limited to small trials.
What intermittent rapamycin dosing is
Rapamycin (generic name sirolimus, brand name Rapamune) is an FDA-approved drug. It prevents kidney transplant rejection and treats a rare lung disease, lymphangioleiomyomatosis (LAM). Rapamycin blocks mTOR (mechanistic target of rapamycin — a protein that senses nutrients and controls cell growth). Intermittent dosing means taking a drug on a spaced-out schedule, like weekly, instead of daily.
How intermittent dosing works
mTOR isn't one switch — it's two, called mTORC1 and mTORC2, built around the same protein. Think of one panel with two dimmer switches. A quick tap dims the first. Only holding it down dims the second. Daily rapamycin "holds the switch down," gradually affecting both. mTORC2 inhibition is linked to metabolic and immune side effects (Kaeberlein, Journals of Gerontology, 2020), so intermittent dosing is hypothesized to tap mTORC1 more selectively.
Who asks about intermittent rapamycin dosing
People come to this topic after reading about mouse longevity studies. They wonder if the same logic applies to humans. Others are transplant patients curious why research schedules differ from their prescribed daily dose.
What the research says about intermittent rapamycin dosing
Rapamycin extended median lifespan by 9 to 14 percent in genetically heterogeneous mice. The mice were studied through the National Institute on Aging's (NIA) Interventions Testing Program (Harrison et al., Nature, 2009). Human data is thinner: a 48-week trial gave 114 healthy adults, ages 50 to 85, weekly rapamycin or placebo. Lean tissue mass and self-reported pain improved in women at the higher dose studied (PEARL trial results, 2025). It did not show whether rapamycin lengthens human lifespan.
What to know before considering rapamycin
Any use outside its approved transplant and LAM indications is off-label and needs physician supervision. Documented risks include immunosuppression (a weakened ability to fight infection), impaired wound healing, and mouth sores (FDA label, 2017). It requires blood-level monitoring and is not something to source independently.
The Halftime POV
Rapamycin sits outside what Halftime Health prescribes today — a transplant drug, not a formulary peptide. We cover it because members ask, and the mTORC1/mTORC2 question is genuinely interesting. We explain the science honestly: promising mouse data, early human data, real risks.
Related reading:
- mTOR: the body's growth-and-repair switch
- Longevity evidence vs. hype
- Healthspan vs. lifespan
- What the 2026 longevity research actually shows
FAQ
Q: What is intermittent rapamycin dosing? A: Intermittent dosing means taking rapamycin on a spaced-out schedule, such as weekly, instead of daily. Researchers study this pattern because it may reduce side effects tied to daily use.
Q: How does intermittent rapamycin dosing work? A: Daily rapamycin inhibits both mTORC1 and mTORC2, two complexes built around the mTOR protein. Intermittent dosing is hypothesized to inhibit mTORC1 more selectively while sparing mTORC2, the complex linked to metabolic and immune side effects.
Q: Is rapamycin FDA-approved? A: It is approved only for preventing organ rejection after kidney transplants and for treating a rare lung disease called LAM. Any other use, including for longevity research purposes, is off-label.
Q: What did the PEARL trial find? A: The PEARL trial, a 48-week randomized study in 114 healthy adults ages 50 to 85, found that lean tissue mass and self-reported pain improved in women taking the higher weekly dose studied.
Q: Can rapamycin be prescribed for longevity? A: Any use outside its approved transplant and LAM indications is off-label and requires a physician's supervision. It is a prescription drug with real risks and is not something to source independently.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We'll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we'll email you when we're live.
Sources
- Rapamycin fed late in life extends lifespan in genetically heterogeneous mice — Harrison et al., Nature, 2009
- Influence of rapamycin on safety and healthspan metrics after one year: PEARL trial results, 2025
- Next Generation Strategies for Geroprotection via mTORC1 Inhibition — Kaeberlein, Journals of Gerontology, 2020
- RAPAMUNE (sirolimus) FDA Prescribing Label, 2017
Frequently asked questions
what is intermittent rapamycin dosing
Intermittent dosing means taking rapamycin on a spaced-out schedule, such as weekly, instead of daily. Researchers study this pattern because it may reduce side effects tied to daily use.
how does intermittent rapamycin dosing work
Daily rapamycin inhibits both mTORC1 and mTORC2, two complexes built around the mTOR protein. Intermittent dosing is hypothesized to inhibit mTORC1 more selectively while sparing mTORC2, the complex linked to metabolic and immune side effects.
is rapamycin FDA-approved
It is approved only for preventing organ rejection after kidney transplants and for treating a rare lung disease called LAM. Any other use, including for longevity research purposes, is off-label.
what did the PEARL trial find
The PEARL trial, a 48-week randomized study in 114 healthy adults ages 50 to 85, found that lean tissue mass and self-reported pain improved in women taking the higher weekly dose studied.
can rapamycin be prescribed for longevity
Any use outside its approved transplant and LAM indications is off-label and requires a physician's supervision. It is a prescription drug with real risks and is not something to source independently.
Keep reading
A licensed physician can build a protocol from your own labs.
Membership from $69/mo, including your onboarding panel. Each protocol is its own monthly subscription.